Luminex (LMNX) 10-Q 28 Oct 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Entity [Abstract]	'	'
Entity Registrant Name	'Luminex Corp	'
Entity Central Index Key	'0001033905	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	42,833,191
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$89,123	$67,924
Short-term investments	0	4,517
Accounts receivable, net	27,354	30,948
Inventories, net	33,129	30,487
Deferred income taxes	8,169	7,265
Prepaids and other	5,293	5,229
Total current assets	163,068	146,370
Property and equipment, net	37,096	32,793
Intangible assets, net	57,346	60,295
Deferred income taxes	11,913	11,913
Long-term investments	7,975	0
Goodwill	49,619	50,738
Other	3,495	3,937
Total assets	330,512	306,046
Current liabilities:	'	'
Accounts payable	10,138	10,698
Accrued liabilities	13,066	11,624
Deferred revenue	5,079	4,980
Current portion of long-term debt	0	1,194
Total current liabilities	28,283	28,496
Long-term debt	0	463
Deferred revenue	2,436	2,482
Other	4,924	4,985
Total liabilities	35,643	36,426
Stockholders' equity:	'	'
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,717,679 shares at September 30, 2014; 41,133,653 shares at December 31, 2013	42	41
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	306,766	296,931
Accumulated other comprehensive (loss) income	-409	419
Accumulated deficit	-11,530	-27,771
Total stockholders' equity	294,869	269,620
Total liabilities and stockholders' equity	$330,512	$306,046

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS Parenthetical (USD $)	Sep. 30, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	41,717,679	41,133,653
Common stock, outstanding (in shares)	41,717,679	41,133,653
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$56,684	$50,780	$168,877	$158,267
Cost of revenue	17,674	19,999	51,766	51,472
Gross profit	39,010	30,781	117,111	106,795
Operating expenses:	'	'	'	'
Research and development	10,327	10,346	32,719	34,852
Selling, general and administrative	21,423	21,466	61,838	67,429
Amortization of acquired intangible assets	964	1,021	2,949	3,077
Restructuring costs	1,300	2,142	1,653	2,142
Total operating expenses	34,014	34,975	99,159	107,500
Income (loss) from operations	4,996	-4,194	17,952	-705
Interest expense from long-term debt	0	-16	-6	-67
Other income, net	-15	6,638	-35	6,730
Income before income taxes	4,981	2,428	17,911	5,958
Income tax benefit (expense)	569	-1,632	-1,670	-3,978
Net income	5,550	796	16,241	1,980
Other comprehensive (loss) income:	'	'	'	'
Foreign currency translation adjustments	-410	106	-814	-515
Unrealized (loss) gain on available-for-sale securities, net of tax	-15	1	-14	-1
Other comprehensive (loss) income	-425	107	-828	-516
Comprehensive income	$5,125	$903	$15,413	$1,464
Net income per share, basic	$0.13	$0.02	$0.39	$0.05
Shares used in computing net income per share, basic	41,714	40,752	41,496	40,712
Net income per share, diluted	$0.13	$0.02	$0.39	$0.05
Shares used in computing net income per share, diluted	42,381	41,919	42,127	41,771

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Document Fiscal Year Focus	'	'	'2014	'
Net income	$5,550	$796	$16,241	$1,980
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	3,400	3,994	10,935	11,747
Stock-based compensation	2,622	1,889	7,052	6,733
Deferred income tax (benefit) expense	-3,568	1,989	-1,048	3,415
Excess income tax (benefit) expense from employee stock-based awards	-1,315	-15	-1,315	274
Loss (gain) on disposal of assets	48	-5,388	231	-5,305
Non-cash restructuring charges	1,192	3,695	2,388	3,695
Other	-28	-34	-360	-1,115
Changes in operating assets and liabilities:	'	'	'	'
Accounts receivable, net	203	1,384	3,742	3,076
Inventories, net	-1,943	1,769	-3,465	-1,914
Other assets	-829	-415	-792	-2,058
Accounts payable	1,227	2,215	-878	-718
Accrued liabilities	4,922	-1,184	407	-2,727
Deferred revenue	46	439	53	409
Net cash provided by operating activities	11,527	11,134	33,191	17,492
Cash flows from investing activities:	'	'	'	'
Purchases of available-for-sale securities	-8,000	-2,997	-10,996	-8,489
Sales and maturities of available-for-sale securities	2,996	2,996	7,509	19,632
Purchase of property and equipment	-5,540	-6,914	-11,795	-15,136
Proceeds from sale of assets	5	9,533	44	9,564
Acquired technology rights	0	0	-64	-930
Net cash (used in) provided by investing activities	-10,539	2,618	-15,302	4,641
Cash flows from financing activities:	'	'	'	'
Payments on debt	0	0	-1,621	-1,105
Proceeds from issuance of common stock	327	5,973	3,807	7,891
Payments for stock repurchases	0	0	0	-14,343
Excess income tax benefit (expense) from employee stock-based awards	1,315	15	1,315	-274
Net cash provided by (used in) financing activities	1,642	5,988	3,501	-7,831
Effect of foreign currency exchange rate on cash	-217	-49	-191	78
Change in cash and cash equivalents	2,413	19,691	21,199	14,380
Cash and cash equivalents, beginning of period	86,710	37,478	67,924	42,789
Cash and cash equivalents, end of period	$89,123	$57,169	$89,123	$57,169

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION	'
	NOTE 1 — BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the “Company” or “Luminex”) in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the "2013 10-K").
	The Company has two segments for financial reporting purposes: the technology and strategic partnerships (“TSP”) segment and the assays and related products (“ARP”) segment.  See Note 10 — Segment Information.

RESTRUCTURING_RESTRUCTURING

RESTRUCTURING RESTRUCTURING	9 Months Ended
	Sep. 30, 2014
RESTRUCTURING [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	NOTE 2 — RESTRUCTURING
	In August 2013, the Company announced a restructuring plan focused on its ARP segment's Newborn Screening Group and its Brisbane, Australia office where automated punching systems were designed and manufactured. The Company halted development of the newborn screening assay in 2013. In the first quarter of 2014, management determined that it would close the manufacturing facility in Brisbane, Australia in the current year and the facility was closed in the third quarter of 2014. The Company reviewed the requirements for held-for-sale and discontinued operations presentation and determined the manufacturing facility in Brisbane, Australia does not meet the altered definition of a discontinued operation under the recent amended accounting guidance as it is not a strategic shift with a major effect on the Company's operations and finances. Management has applied this new guidance for the facility in Brisbane, Australia.
	The Company has recorded pre-tax restructuring charges primarily consisting of non-cash impairment of inventory, intangible assets and property and equipment, together with employee separation costs. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits. As a result of the organizational change, the Company eliminated approximately 5% of its aggregate workforce. In conjunction with the restructuring plan, the Company evaluated its tangible and intangible assets for estimated impairment and recorded non-cash impairment charges of $4.1 million in 2013 and a further impairment of $2.4 million in the first nine months of 2014, including a write-down of goodwill of $1.2 million resulting from the disposal of the manufacturing facility in Brisbane, Australia. The Company determined the fair value of the assets based upon prices for similar assets. The amount of goodwill the Company included in the carrying amount of the disposed manufacturing facility in Brisbane, Australia was based upon the relative fair value of that business compared to the portion of the reporting unit that was retained.  See Note 6 — Goodwill and Other Intangible Assets.
	The Company measured and accrued the facilities exit costs at fair value upon the Company's exit in the third quarter. Facilities exit costs primarily consist of cease-use losses recorded upon vacating the facilities.
	The following tables display the charges taken related to the restructuring through September 30, 2014 and a rollforward of the charges to the accrued balance as of September 30, 2014 (in thousands):
	Restructuring Charges				2013 Restructuring Plan
	2013
	Non-cash impairment charges:
	Inventory				$	2,326
	Property and equipment				1,110
	Intangible assets				700
	Employee separation costs				783
	Other				50
	Total 2013 charges				$	4,969
	Recorded to cost of revenue				2,551
	Recorded to restructuring costs				$	2,418
	2014
	Non-cash impairment charges:
	Inventory				$	964
	Property and equipment				265
	Goodwill				1,159
	Employee separation costs				154
	Facility exit costs				69
	Other				41
	Total 2014 charges				$	2,652
	Recorded to cost of revenue				999
	Recorded to restructuring costs				$	1,653
	Rollforward of Accrued Restructuring	September 30, 2014			December 31, 2013
	Balance at beginning of year	$	128		$	—
	Total restructuring charges	2,652			4,969
	Non-cash impairment charges	(2,388		)	(4,136		)
	Employee separation payments	(213		)	(655		)
	Facility exit costs	(69		)	—
	Foreign exchange and other adjustments	(38		)	(50		)
	Balance at end of period	$	72		$	128
	The remaining restructuring accrual balance is expected to be paid in October 2014. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of September 30, 2014.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2014
Investments [Abstract]	'
INVESTMENTS	'
	NOTE 3 — INVESTMENTS
	Marketable Securities
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.  Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings.  Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates the fair value of these investments.   Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity.  As of September 30, 2014 and December 31, 2013, all of the Company’s marketable securities were classified as available for sale.  Marketable securities are recorded as either short-term or long-term on the balance sheet based on the contractual maturity date.  The fair value of all securities is determined by quoted market prices, market interest rates inputs, or other than quoted prices that are observable either directly or indirectly (as of the end of the reporting period).  Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
	Available-for-sale securities consisted of the following as of September 30, 2014 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	12,322	$	—	$	—		$	12,322
	Non-government sponsored debt securities	—		—		—			—
	Total current securities	12,322		—		—			12,322
	Noncurrent:
	Government sponsored debt securities	4,000		—		(4		)	3,996
	Non-government sponsored debt securities	4,000		—		(21		)	3,979
	Total noncurrent securities	8,000		—		(25		)	7,975
	Total available-for-sale securities	$	20,322	$	—	$	(25	)	$	20,297
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—		$	46,422
	Non-government sponsored debt securities	4,517		—		—			4,517
	Total current securities	50,939		—		—			50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—			—
	Total noncurrent securities	—		—		—			—
	Total available-for-sale securities	$	50,939	$	—	$	—		$	50,939
	There were no proceeds from the sales of available-for-sale securities during the three months ended September 30, 2014 or 2013. Realized gains and losses on sales of investments are determined using the specific identification method.  Realized gains and losses are included in other income (expense) in the Consolidated Statements of Comprehensive Income. All of the Company's available-for-sale securities with gross unrealized holding losses as of September 30, 2014 and December 31, 2013 had been in a loss position for less than 12 months.
	The estimated fair value of available-for-sale debt securities at September 30, 2014 and December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		September 30, 2014		December 31, 2013
	Due in one year or less	$	—	$	4,517
	Due after one year through two years	7,975		—
		$	7,975	$	4,517
	Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
	Non-Marketable Securities and Other-Than-Temporary Impairment
	The Company owns a minority interest in a private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012.  This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee as the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded.
	The Company's other minority interest in a private company was acquired by a third party in July 2013. The Company realized a gain of $5.4 million on this minority interest investment in the third quarter of 2013.
	The Company regularly evaluates the carrying value of its cost-method investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee's ability to remain in business, such as the investee's liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income, net in the Consolidated Statements of Comprehensive Income (Loss). As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, this cost-method investment is classified within Level 3 of the fair value hierarchy. To determine the fair value of this investment, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost-method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical.

INVENTORY_NET

INVENTORY, NET	9 Months Ended
	Sep. 30, 2014
Inventory, Net [Abstract]	'
INVENTORIES, NET	'
	NOTE 4 — INVENTORIES, NET
	Inventories are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method.  The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Inventories consisted of the following (in thousands):
		September 30, 2014		December 31, 2013
	Parts and supplies	$	16,988	$	19,002
	Work-in-progress	8,192		4,747
	Finished goods	7,949		6,738
		$	33,129	$	30,487

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 5 — FAIR VALUE MEASUREMENT
	The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:
	Level 1 –	Quoted prices in active markets for identical assets or liabilities.
	Level 2 –	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 –	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value.  There were no transfers between Level 1, Level 2, or Level 3 measurements for the three month period ended September 30, 2014.
	We record contingent consideration resulting from a business combination at its fair value on the acquisition date. The Company determines the fair value of the contingent consideration based primarily on the timing and probability of success of clinical events or regulatory approvals, the timing and probability of success of meeting commercial milestones, such as sales levels of a specific product, and discount rates. Our contingent consideration liability arose in connection with the GenturaDx, Inc. ("GenturaDx") acquisition. The Company re-evaluates its assumptions for its contingent consideration fair value determinations each quarter. Changes to the fair value of contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in our estimates of the likelihood of or timing of achieving any development or commercial milestones, changes in the probability of certain clinical events or changes in the assumed probability associated with regulatory approval. As a result of changes in assumptions surrounding the probability of success of meeting the timing of commercial milestones contemplated in the GenturaDx acquisition agreement, the Company adjusted the contingent consideration liability related to the GenturaDx acquisition to $0 in 2013. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.
	As of September 30, 2014 and December 31, 2013 the fair value of the Company's long-term debt was $0 and approximately $1.5 million, respectively. In May 2014, the Company repaid all of its outstanding debt.
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013 (in thousands):
		Fair Value Measurements at September 30, 2014 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	12,322	$	—		$	—	$	12,322
	Government and non-government sponsored debt securities	—		7,975			—		7,975
		Fair Value Measurements at December 31, 2013 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	46,422	$	—		$	—	$	46,422
	Non-government sponsored debt securities	—		4,517			—		4,517
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		September 30, 2014		December 31, 2013
	Balance at beginning of year	$	—	$	1,370
	Contingent consideration recorded at acquisition	—		—
	Fair value adjustments	—		(1,370		)
	Balance at end of period	$	—	$	—

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS
	All of the Company's goodwill relates to one reporting unit, the ARP segment, for goodwill impairment testing.  Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. The Company has not yet completed its annual analysis and is currently evaluating the impact of recent changes in product commercialization timelines. The estimated fair value of the ARP segment may not exceed its carrying value which would require the Company to perform further analysis to determine if goodwill is impaired.  This goodwill is not expected to be deductible for tax purposes.
	In connection with the closure of the manufacturing facility in Brisbane, Australia in the third quarter of 2014, the Company has recorded a write-down of goodwill of $1.2 million. The amount of goodwill the Company included in the carrying amount of the disposed manufacturing business in Brisbane, Australia was based upon the relative fair value of that facility compared to the portion of the reporting unit that was retained.
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		September 30, 2014			December 31, 2013
	Balance at beginning of year	$	50,738		$	51,128
	Allocation in disposal of Brisbane, Australia business (See Note 2)	(1,159		)	—
	Foreign currency translation adjustments	40			(390		)
	Balance at end of period	$	49,619		$	50,738
	The current in-process research and development project is related to the Company's acquisition of GenturaDx, the foundation of our ARIESTM System, in 2012 and is scheduled to be completed and commercialized in 2015.  The estimated aggregate costs to complete this project are between $4.0 million and $7.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(916		)	(168		)	(258		)	(454		)	(1,796		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	28,974			7,791			1,642			40,100			78,507
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Write-off / Impairment	702			161			238			—			1,101
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(15,570		)	(2,165		)	(477		)	—			(18,212		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
	2014
	Balance at December 31, 2013	$	28,974		$	7,791		$	1,642		$	40,100		$	78,507
	Foreign currency translation adjustments	39			9			13			—			61
	Balance at September 30, 2014	29,013			7,800			1,655			40,100			78,568
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2013	(15,570		)	(2,165		)	(477		)	—			(18,212		)
	Amortization expense	(2,280		)	(567		)	(102		)	—			(2,949		)
	Foreign currency translation adjustments	(39		)	(9		)	(13		)	—			(61		)
	Accumulated amortization balance at September 30, 2014	(17,889		)	(2,741		)	(592		)	—			(21,222		)
	Net balance at September 30, 2014	$	11,124		$	5,059		$	1,063		$	40,100		$	57,346
	Weighted average life (in years)	10			11			11
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2014 (three months)	$	964
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,852
		17,246
	IP R&D	40,100
		$	57,346

OTHER_COMPREHENSIVE_LOSS_INCOM

OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note	'
	NOTE 7 — OTHER COMPREHENSIVE (LOSS) INCOME
	Other comprehensive (loss) income represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive (loss) income for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive (Loss) Income Items
	Beginning balance, December 31, 2013	$	419		$	—		$	419
	Other comprehensive loss before reclassifications	(814		)	(7		)	(821		)
	Amounts reclassified from accumulated other comprehensive (loss) income	—			(7		)	(7		)
	Net current-period other comprehensive loss	(814		)	(14		)	(828		)
	Ending balance, September 30, 2014	$	(395	)	$	(14	)	$	(409	)
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Three Months Ended September 30, 2014									Nine Months Ended September 30, 2014
		Before Tax			Tax Benefit			Net of Tax			Before Tax			Tax Benefit		Net of Tax
	Foreign currency translation adjustments	$	(410	)	$	—		$	(410	)	$	(814	)	$	—	$	(814	)
	Unrealized losses on available-for-sale investments	(24		)	9			(15		)	(23		)	9		(14		)
	Other comprehensive (loss) income	$	(434	)	$	9		$	(425	)	$	(837	)	$	9	$	(828	)

EARNINGS_PER_SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 8 — EARNINGS PER SHARE
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Numerator:
	Net income	$	5,550	$	796	$	16,241	$	1,980
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	41,714		40,752		41,496		40,712
	Effect of dilutive securities: stock options and awards	667		1,167		631		1,059
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	42,381		41,919		42,127		41,771
	Basic net income per share	$	0.13	$	0.02	$	0.39	$	0.05
	Diluted net income per share	$	0.13	$	0.02	$	0.39	$	0.05
	Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period.  Restricted stock (consisting of restricted stock awards, or RSAs, and restricted stock units, or RSUs) and stock options to acquire approximately 0.2 million and 0.2 million shares for the three months ended September 30, 2014 and 2013, respectively, and 0.2 million and 0.2 million shares for the nine months ended September 30, 2014 and 2013, respectively, were excluded from the computations of diluted EPS because the effect of including those RSAs, RSUs, and stock options would have been anti-dilutive.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	NOTE 9 — STOCK-BASED COMPENSATION
	The Company’s stock option activity for the nine months ended September 30, 2014 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2013	967		$	15.35
	Granted	—		—
	Exercised	(311	)	9.73
	Cancelled or expired	(25	)	19.85
	Outstanding at September 30, 2014	631		$	17.94
	The Company had $1.0 million of total unrecognized compensation costs related to stock options at September 30, 2014 that are expected to be recognized over a weighted average period of 1.14 years years.
	The Company’s restricted share activity for the nine months ended September 30, 2014 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2013	826		$	18.62
	Granted	535		20.04
	Vested	(285	)	18.08
	Cancelled or expired	(59	)	19.23
	Non-vested at September 30, 2014	1,017		$	19.48
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2013	833
	Granted	139
	Vested	(59	)
	Cancelled or expired	(168	)
	Non-vested at September 30, 2014	745
	As of September 30, 2014, there was $18.5 million and $4.3 million of unrecognized compensation costs related to RSAs and RSUs, respectively. That cost is expected to be recognized over a weighted average period of 2.99 years years for the RSAs and 2.02 years years for the RSUs. The Company issues a small number of cash settled restricted stock units pursuant to the Company's equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company.
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2014			2013		2014		2013
	Cost of revenue	$	233		$	233	$	743	$	635
	Research and development	726			675		1,862		1,892
	Selling, general and administrative	1,663			981		4,447		4,206
	Stock-based compensation costs reflected in net income	$	2,622		$	1,889	$	7,052	$	6,733

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 10 — SEGMENT INFORMATION
	Management has determined that the Company has two segments for financial reporting purposes:  the TSP segment and the ARP segment.  The accounting principles of the segments are the same as those described in the Summary of Significant Accounting Policies in the Company's 2013 10-K.
	Intersegment sales are recorded at fixed prices that approximate the prices charged to third party strategic partners and are not a measure of segment operating earnings. Intersegment sales of approximately $3.6 million and $2.2 million for the quarters ending September 30, 2014 and 2013, and $9.0 million and $7.9 million for the nine months ended September 30, 2014 and 2013, respectively, have been eliminated upon consolidation.  The following is selected segment information for the periods indicated (in thousands):
		Three Months Ended September 30, 2014							Three Months Ended September 30, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	32,645	$	24,039		$	56,684	$	33,335	$	17,445		$	50,780
	Depreciation and amortization	1,655		1,745			$	3,400	2,087		1,907			$	3,994
	Operating profit (loss)	8,792		(3,796		)	$	4,996	9,293		(13,487		)	$	(4,194	)
	Segment assets	174,548		155,964			$	330,512	187,422		106,474			$	293,896
		Nine Months Ended September 30, 2014							Nine Months Ended September 30, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	98,094	$	70,783		$	168,877	$	96,352	$	61,915		$	158,267
	Depreciation and amortization	5,373		5,562			$	10,935	5,826		5,921			$	11,747
	Operating profit (loss)	27,348		(9,396		)	$	17,952	23,368		(24,073		)	$	(705	)
	Segment assets	174,548		155,964			$	330,512	187,422		106,474			$	293,896

ACCRUED_WARRANTY_COSTS

ACCRUED WARRANTY COSTS	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
ACCRUED WARRANTY COSTS	'
	NOTE 11 — ACCRUED WARRANTY COSTS
	Sales of certain of the Company's systems are subject to a warranty.  System warranties typically extend for a period of 12 months from the date of installation not to exceed 24 months from the date of shipment.  The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data.  The actual warranty expense could differ from the estimates made by the Company based on product performance.  Warranty expenses are evaluated and adjusted periodically.
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2013	$	721
	Warranty expenses incurred	728
	Accrual for warranty costs	(773		)
	Accrued warranty costs at September 30, 2014	$	676

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 12 — INCOME TAXES
	At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year.  The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the nine months ended September 30, 2014 was 9.30%, including amounts recorded for discrete events. This differs from the statutory rate of 35% primarily because of the worldwide mix of consolidated earnings and losses before taxes and an assessment regarding the realizability of the Company’s deferred tax assets.  The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates.  The Company is utilizing its net operating losses in the U.S., Canada, and the Netherlands; currently expects a full year effective tax rate of less than 20%, and therefore cash taxes to be paid are expected to continue to be less than 50% of book tax expense.
	The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, Hong Kong, Japan, the Netherlands, and various states.  Due to net operating losses, the U.S., Canadian and Australian tax returns dating back to 2009, 2009, and 2010, respectively, can still be reviewed by the taxing authorities.  No other material changes to this liability are expected within the next 12 months.  For the nine months ended September 30, 2014, there were no material changes to the total amount of unrecognized tax benefits.  The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 13 - COMMITMENTS AND CONTINGENCIES
	On August 30, 2012 Abbott Laboratories ("Abbott") was named as a defendant in the complaint filed by ENZO Life Sciences, Inc. ("ENZO") in U.S. District Court in Delaware for alleged infringement of its US Patent 7,064,197 as a result of Abbott's distribution of the Company's xTAG Respiratory Viral Panel.  The Company and Abbott have entered into an agreement requiring the Company to defend and indemnify Abbott for any alleged infringement resulting from its distribution of the Company's xTAG Respiratory Viral Panel. The complaint seeks unspecified monetary damages and injunctive relief.  Abbott filed an answer to the complaint on October 15, 2012.  On November 30, 2012, the Company intervened in the lawsuit. On January 2, 2013 ENZO filed additional claims against the Company, alleging infringement of US Patent 7,064,197 resulting from the Company's sale of its xTAG, FlexScript LDA, SelecTAG, and xMAP Salmonella Serotyping Assay products and alleging infringement of US Patent 8,097,405 resulting from the Company's sale of Multicode products.  The Company filed an answer to ENZO's additional claims on January 28, 2013.  On October 2, 2013 ENZO filed additional claims against the Company, alleging infringement of U.S. Patent 6,992,180 resulting from the Company’s sale of Multicode products.  The Company filed an answer to ENZO’s additional claims on October 21, 2013. A trial date has not been set. The parties to the lawsuit have engaged in the discovery process.
	On November 1, 2013 Irori Technologies, Inc. ("Irori") filed a complaint against the Company in U.S. District Court in the Southern District of California, alleging infringement of its US Patent 6,372,428, 6,416,714, and 6,352,854 resulting from the Company’s sale of its xMAP and xTAG based products. The Company filed a motion to dismiss on January 9, 2014.  Irori filed its response to the Company's motion to dismiss on February 7, 2014.  The court granted the Company's motion to dismiss without prejudice on February 25, 2014.  On March 18, 2014, Irori filed an amended complaint, again alleging infringement of its US Patent 6,372,428, 6,416,714, and 6,352,854 resulting from the Company’s sale of its xMAP and xTAG based products.  The complaint seeks unspecified monetary damages and injunctive relief. The Company filed an answer to Irori’s amended complaint on April 2, 2014.  On June 10, 2014 the Company filed with the United States Patent and Trademark Office's ("USPTO’s") Patent Trial and Appeal Board a total of five petitions for inter partes review seeking to invalidate the claims of the three patents involved in the litigation.   On June 17, 2014, the Company filed a motion to stay proceedings in the district court pending the USPTO’s resolution of the inter partes review of Irori’s patents.  Irori filed its opposition to the motion to stay on July 7, 2014, and the Company filed a reply on July 14, 2014.  On July 16, 2014, the court granted the Company’s motion to stay the case until the earlier of i) a determination by the USPTO that reexamination proceedings will not take place or ii) the conclusion of reexamination proceedings and appeals.  A trial date has not been set.
	When and if it appears probable in management's judgment, and based upon consultation with outside counsel, that the Company will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, the Company records the estimated liability in the financial statements.  If only a range of estimated losses can be estimated, the Company records an amount within the range that, in management's judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, the Company records the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. The Company discloses significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when the Company believes there is at least a reasonable possibility that a loss has been incurred. The Company recognizes costs associated with legal proceedings in the period in which the services were provided. There can be no assurance that the Company will successfully defend these suits or that a judgment against the Company would not materially adversely affect operating results.
	In January 2013, the Company finalized the termination of its molecular diagnostics distribution agreements and an expense of $7.0 million was recorded in selling, general and administrative expenses in the first quarter of 2013. All payments were made in the second quarter of 2013.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 14 — RECENT ACCOUNTING PRONOUNCEMENTS
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. For the Company, the changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. Management applied this new guidance for the automated punching group and the related closure of the Brisbane, Australia manufacturing facility in the third quarter of 2014.
	In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

RESTRUCTURING_RESTRUCTURING_Ta

RESTRUCTURING RESTRUCTURING (Tables)	9 Months Ended
	Sep. 30, 2014
RESTRUCTURING [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
	Restructuring Charges				2013 Restructuring Plan
	2013
	Non-cash impairment charges:
	Inventory				$	2,326
	Property and equipment				1,110
	Intangible assets				700
	Employee separation costs				783
	Other				50
	Total 2013 charges				$	4,969
	Recorded to cost of revenue				2,551
	Recorded to restructuring costs				$	2,418
	2014
	Non-cash impairment charges:
	Inventory				$	964
	Property and equipment				265
	Goodwill				1,159
	Employee separation costs				154
	Facility exit costs				69
	Other				41
	Total 2014 charges				$	2,652
	Recorded to cost of revenue				999
	Recorded to restructuring costs				$	1,653
	Rollforward of Accrued Restructuring	September 30, 2014			December 31, 2013
	Balance at beginning of year	$	128		$	—
	Total restructuring charges	2,652			4,969
	Non-cash impairment charges	(2,388		)	(4,136		)
	Employee separation payments	(213		)	(655		)
	Facility exit costs	(69		)	—
	Foreign exchange and other adjustments	(38		)	(50		)
	Balance at end of period	$	72		$	128
	The remaining restructuring accrual balance is expected to be paid in October 2014. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of September 30, 2014.

INVESTMENTS_Tables

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Investments [Abstract]	'
Components of available-for-sale securities	'
	Available-for-sale securities consisted of the following as of September 30, 2014 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	12,322	$	—	$	—		$	12,322
	Non-government sponsored debt securities	—		—		—			—
	Total current securities	12,322		—		—			12,322
	Noncurrent:
	Government sponsored debt securities	4,000		—		(4		)	3,996
	Non-government sponsored debt securities	4,000		—		(21		)	3,979
	Total noncurrent securities	8,000		—		(25		)	7,975
	Total available-for-sale securities	$	20,322	$	—	$	(25	)	$	20,297
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—		$	46,422
	Non-government sponsored debt securities	4,517		—		—			4,517
	Total current securities	50,939		—		—			50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—			—
	Total noncurrent securities	—		—		—			—
	Total available-for-sale securities	$	50,939	$	—	$	—		$	50,939
Estimated fair value of available-for-sale debt securities, by contractual maturity	'
	The estimated fair value of available-for-sale debt securities at September 30, 2014 and December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		September 30, 2014		December 31, 2013
	Due in one year or less	$	—	$	4,517
	Due after one year through two years	7,975		—
		$	7,975	$	4,517

INVENTORY_NET_Tables

INVENTORY, NET (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory, Net [Abstract]	'
Schedule of Inventory, Current	'
	Inventories consisted of the following (in thousands):
		September 30, 2014		December 31, 2013
	Parts and supplies	$	16,988	$	19,002
	Work-in-progress	8,192		4,747
	Finished goods	7,949		6,738
		$	33,129	$	30,487

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013 (in thousands):
		Fair Value Measurements at September 30, 2014 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	12,322	$	—		$	—	$	12,322
	Government and non-government sponsored debt securities	—		7,975			—		7,975
		Fair Value Measurements at December 31, 2013 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	46,422	$	—		$	—	$	46,422
	Non-government sponsored debt securities	—		4,517			—		4,517
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	'
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		September 30, 2014		December 31, 2013
	Balance at beginning of year	$	—	$	1,370
	Contingent consideration recorded at acquisition	—		—
	Fair value adjustments	—		(1,370		)
	Balance at end of period	$	—	$	—

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		September 30, 2014			December 31, 2013
	Balance at beginning of year	$	50,738		$	51,128
	Allocation in disposal of Brisbane, Australia business (See Note 2)	(1,159		)	—
	Foreign currency translation adjustments	40			(390		)
	Balance at end of period	$	49,619		$	50,738
Schedule of intangible assets	'
	The current in-process research and development project is related to the Company's acquisition of GenturaDx, the foundation of our ARIESTM System, in 2012 and is scheduled to be completed and commercialized in 2015.  The estimated aggregate costs to complete this project are between $4.0 million and $7.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(916		)	(168		)	(258		)	(454		)	(1,796		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	28,974			7,791			1,642			40,100			78,507
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Write-off / Impairment	702			161			238			—			1,101
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(15,570		)	(2,165		)	(477		)	—			(18,212		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
	2014
	Balance at December 31, 2013	$	28,974		$	7,791		$	1,642		$	40,100		$	78,507
	Foreign currency translation adjustments	39			9			13			—			61
	Balance at September 30, 2014	29,013			7,800			1,655			40,100			78,568
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2013	(15,570		)	(2,165		)	(477		)	—			(18,212		)
	Amortization expense	(2,280		)	(567		)	(102		)	—			(2,949		)
	Foreign currency translation adjustments	(39		)	(9		)	(13		)	—			(61		)
	Accumulated amortization balance at September 30, 2014	(17,889		)	(2,741		)	(592		)	—			(21,222		)
	Net balance at September 30, 2014	$	11,124		$	5,059		$	1,063		$	40,100		$	57,346
	Weighted average life (in years)	10			11			11
Estimated aggregate amortization expense for the next five years and thereafter	'
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2014 (three months)	$	964
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,852
		17,246
	IP R&D	40,100
		$	57,346

OTHER_COMPREHENSIVE_LOSS_INCOM1

OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	9 Months Ended
	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive (Loss) Income Items
	Beginning balance, December 31, 2013	$	419		$	—		$	419
	Other comprehensive loss before reclassifications	(814		)	(7		)	(821		)
	Amounts reclassified from accumulated other comprehensive (loss) income	—			(7		)	(7		)
	Net current-period other comprehensive loss	(814		)	(14		)	(828		)
	Ending balance, September 30, 2014	$	(395	)	$	(14	)	$	(409	)
Schedule of Comprehensive Income (Loss)	'
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Three Months Ended September 30, 2014									Nine Months Ended September 30, 2014
		Before Tax			Tax Benefit			Net of Tax			Before Tax			Tax Benefit		Net of Tax
	Foreign currency translation adjustments	$	(410	)	$	—		$	(410	)	$	(814	)	$	—	$	(814	)
	Unrealized losses on available-for-sale investments	(24		)	9			(15		)	(23		)	9		(14		)
	Other comprehensive (loss) income	$	(434	)	$	9		$	(425	)	$	(837	)	$	9	$	(828	)

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Numerator:
	Net income	$	5,550	$	796	$	16,241	$	1,980
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	41,714		40,752		41,496		40,712
	Effect of dilutive securities: stock options and awards	667		1,167		631		1,059
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	42,381		41,919		42,127		41,771
	Basic net income per share	$	0.13	$	0.02	$	0.39	$	0.05
	Diluted net income per share	$	0.13	$	0.02	$	0.39	$	0.05

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options activity	'
	The Company’s stock option activity for the nine months ended September 30, 2014 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2013	967		$	15.35
	Granted	—		—
	Exercised	(311	)	9.73
	Cancelled or expired	(25	)	19.85
	Outstanding at September 30, 2014	631		$	17.94
Restricted shares activity	'
	The Company’s restricted share activity for the nine months ended September 30, 2014 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2013	826		$	18.62
	Granted	535		20.04
	Vested	(285	)	18.08
	Cancelled or expired	(59	)	19.23
	Non-vested at September 30, 2014	1,017		$	19.48
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2013	833
	Granted	139
	Vested	(59	)
	Cancelled or expired	(168	)
	Non-vested at September 30, 2014	745
Stock-based compensation costs recognized in consolidated statements of income	'
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2014			2013		2014		2013
	Cost of revenue	$	233		$	233	$	743	$	635
	Research and development	726			675		1,862		1,892
	Selling, general and administrative	1,663			981		4,447		4,206
	Stock-based compensation costs reflected in net income	$	2,622		$	1,889	$	7,052	$	6,733

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
	The following is selected segment information for the periods indicated (in thousands):
		Three Months Ended September 30, 2014							Three Months Ended September 30, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	32,645	$	24,039		$	56,684	$	33,335	$	17,445		$	50,780
	Depreciation and amortization	1,655		1,745			$	3,400	2,087		1,907			$	3,994
	Operating profit (loss)	8,792		(3,796		)	$	4,996	9,293		(13,487		)	$	(4,194	)
	Segment assets	174,548		155,964			$	330,512	187,422		106,474			$	293,896
		Nine Months Ended September 30, 2014							Nine Months Ended September 30, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	98,094	$	70,783		$	168,877	$	96,352	$	61,915		$	158,267
	Depreciation and amortization	5,373		5,562			$	10,935	5,826		5,921			$	11,747
	Operating profit (loss)	27,348		(9,396		)	$	17,952	23,368		(24,073		)	$	(705	)
	Segment assets	174,548		155,964			$	330,512	187,422		106,474			$	293,896

ACCRUED_WARRANTY_COSTS_Tables

ACCRUED WARRANTY COSTS (Tables)	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
Changes in warranty accrual	'
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2013	$	721
	Warranty expenses incurred	728
	Accrual for warranty costs	(773		)
	Accrued warranty costs at September 30, 2014	$	676

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details)	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of segments for financial reporting purposes (in number of segments)	2

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Asset Impairment Charges	'	$2,388	$4,136	'
Employee Separation Costs	154	'	783	'
Facility Exit Costs	69	-69	0	'
Other Restructuring Costs	41	'	50	'
Total Restructuring Charges	2,652	2,652	4,969	'
Restructuring Charges Included In Cost Of Revenue	999	'	2,551	'
Restructuring Charges And Associated Cost	1,653	'	2,418	'
Employee Separation Payments	'	-213	-655	'
Foreign Exchange and Other Adjustments	'	-38	-50	'
Restructuring Reserve	72	72	128	0
Restructuring and Related Cost, Number of Positions Eliminated, Percent	5.00%	'	'	'
Inventories [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Asset Impairment Charges	964	'	2,326	'
Property, Plant and Equipment [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Asset Impairment Charges	265	'	1,110	'
Goodwill [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Asset Impairment Charges	-1,159	'	0	'
Intangible assets (restructuring) [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Asset Impairment Charges	'	'	$700	'

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	$20,322,000	$20,322,000	'	$50,939,000
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	-25,000	'	0
Estimated Fair Value	20,297,000	20,297,000	'	50,939,000
Available-for-sale Securities [Abstract]	'	'	'	'
Proceeds from sales of available-for-sale-securities	0	'	0	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'	'
Due in one year or less	0	0	'	4,517,000
Due after one year through two years	7,975,000	7,975,000	'	0
Total estimated fair value of available-for-sale debt securities	7,975,000	7,975,000	'	4,517,000
Ownership percentage in cost method investment	20.00%	20.00%	'	'
Money Market Funds [Member]	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	12,322,000	12,322,000	'	46,422,000
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	0	'	0
Estimated Fair Value	12,322,000	12,322,000	'	46,422,000
Current Non-Government Sponsored Debt Securities [Member]	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	0	0	'	4,517,000
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	0	'	0
Estimated Fair Value	0	0	'	4,517,000
Total Current Available-for-sale Securities [Member]	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	12,322,000	12,322,000	'	50,939,000
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	0	'	0
Estimated Fair Value	12,322,000	12,322,000	'	50,939,000
Non-current government sponsored debt securities	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	4,000,000	4,000,000	'	'
Gains in Accumulated Other Comprehensive Gain	'	0	'	'
Losses in Accumulated Other Comprehensive Gain	'	-4,000	'	'
Estimated Fair Value	3,996,000	3,996,000	'	'
Non-Current Non-Government Sponsored Debt Securities [Member]	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	4,000,000	4,000,000	'	0
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	-21,000	'	0
Estimated Fair Value	3,979,000	3,979,000	'	0
Total Non-Current Available-for-sale Securities [Member]	'	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'	'
Amortized Cost	8,000,000	8,000,000	'	0
Gains in Accumulated Other Comprehensive Gain	'	0	'	0
Losses in Accumulated Other Comprehensive Gain	'	-25,000	'	0
Estimated Fair Value	7,975,000	7,975,000	'	0
Investment in Private Company 1 [Member]	'	'	'	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'	'
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	5,400,000	'	'	'
Investment in Private Company 2 [Member]	'	'	'	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'	'
Amount of investments in a private company	$1,000,000	$1,000,000	'	'

INVENTORY_NET_Details

INVENTORY, NET (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Parts and supplies	$16,988	$19,002
Work-in-progress	8,192	4,747
Finished goods	7,949	6,738
Inventory, net	$33,129	$30,487

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	$12,322,000	$46,422,000
Non-government sponsored debt securities	7,975,000	4,517,000
Amounts included in liability accounts [Abstract]	'	'
Contingent consideration	'	0
Long-term debt	0	1,500,000
Fair Value, Inputs, Level 1 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	12,322,000	46,422,000
Non-government sponsored debt securities	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	0	0
Non-government sponsored debt securities	7,975,000	4,517,000
Fair Value, Inputs, Level 3 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	0	0
Non-government sponsored debt securities	$0	$0

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (Fair Value, Inputs, Level 3 [Member], USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance at beginning of year	$0	$1,370
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	0	0
Fair value adjustments	0	-1,370
Balance at end of period	$0	$0

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Intangible Assets [Line Items]	'	'	'	'	'
Asset Impairment Charges	'	'	$2,388,000	'	$4,136,000
Goodwill [Roll Forward]	'	'	'	'	'
Balance at beginning of year	'	'	50,738,000	51,128,000	51,128,000
Foreign currency translation adjustments	'	'	40,000	'	-390,000
Balance at end of period	49,619,000	'	49,619,000	'	50,738,000
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Balance, beginning	'	'	78,507,000	80,584,000	80,584,000
Write Off Of In Process Research And Development Projects	'	'	'	'	-1,796,000
Foreign currency translation adjustments	'	'	61,000	'	-281,000
Balance, ending	78,568,000	'	78,568,000	'	78,507,000
Less: accumulated amortization [Abstract]	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-18,212,000	-15,366,000	-15,366,000
Amortization expense	-964,000	-1,021,000	-2,949,000	-3,077,000	-4,099,000
Write Off Of In Process Research And Development Amortization	'	'	'	'	1,101,000
Foreign currency translation adjustments	-61,000	'	-61,000	'	152,000
Accumulated amortization, ending balance	-21,222,000	'	-21,222,000	'	-18,212,000
Net balance	57,346,000	'	57,346,000	'	60,295,000
Estimated aggregate amortization expense for the next five years and thereafter [Abstract]	'	'	'	'	'
2014 (three months)	964,000	'	964,000	'	'
2015	3,232,000	'	3,232,000	'	'
2016	3,100,000	'	3,100,000	'	'
2017	2,144,000	'	2,144,000	'	'
2018	1,954,000	'	1,954,000	'	'
Thereafter	5,852,000	'	5,852,000	'	'
Total	17,246,000	'	17,246,000	'	'
IP R&D	40,100,000	'	40,100,000	'	'
Total	57,346,000	'	57,346,000	'	'
In-process Research and Development [Member]	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Balance, beginning	'	'	40,100,000	40,627,000	40,627,000
Write Off Of In Process Research And Development Projects	'	'	'	'	-454,000
Foreign currency translation adjustments	'	'	0	'	-73,000
Balance, ending	40,100,000	'	40,100,000	'	40,100,000
Less: accumulated amortization [Abstract]	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	0	0	0
Amortization expense	'	'	0	'	0
Write Off Of In Process Research And Development Amortization	'	'	'	'	0
Foreign currency translation adjustments	0	'	0	'	0
Accumulated amortization, ending balance	0	'	0	'	0
Net balance	40,100,000	'	40,100,000	'	40,100,000
Technology, Trade Secrets, and Know-how [Member]	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Balance, beginning	'	'	28,974,000	30,030,000	30,030,000
Write Off Of In Process Research And Development Projects	'	'	'	'	-916,000
Finite-Lived Intangible Assets, Translation Adjustments	'	'	39,000	'	'
Foreign currency translation adjustments	'	'	'	'	-140,000
Balance, ending	29,013,000	'	29,013,000	'	28,974,000
Less: accumulated amortization [Abstract]	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-15,570,000	-13,193,000	-13,193,000
Amortization expense	'	'	-2,280,000	'	-3,172,000
Write Off Of In Process Research And Development Amortization	'	'	'	'	702,000
Foreign currency translation adjustments	-39,000	'	-39,000	'	93,000
Accumulated amortization, ending balance	-17,889,000	'	-17,889,000	'	-15,570,000
Net balance	11,124,000	'	11,124,000	'	13,404,000
Weighted average life (in years)	'	'	'10 years	'	'10 years
Customer Lists and Contracts [Member]	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Balance, beginning	'	'	7,791,000	7,986,000	7,986,000
Write Off Of In Process Research And Development Projects	'	'	'	'	-168,000
Finite-Lived Intangible Assets, Translation Adjustments	'	'	9,000	'	'
Foreign currency translation adjustments	'	'	'	'	-27,000
Balance, ending	7,800,000	'	7,800,000	'	7,791,000
Less: accumulated amortization [Abstract]	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-2,165,000	-1,560,000	-1,560,000
Amortization expense	'	'	-567,000	'	-787,000
Write Off Of In Process Research And Development Amortization	'	'	'	'	161,000
Foreign currency translation adjustments	-9,000	'	-9,000	'	21,000
Accumulated amortization, ending balance	-2,741,000	'	-2,741,000	'	-2,165,000
Net balance	5,059,000	'	5,059,000	'	5,626,000
Weighted average life (in years)	'	'	'11 years	'	'11 years
Other Identifiable Intangible Assets [Member]	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Balance, beginning	'	'	1,642,000	1,941,000	1,941,000
Write Off Of In Process Research And Development Projects	'	'	'	'	-258,000
Finite-Lived Intangible Assets, Translation Adjustments	'	'	13,000	'	'
Foreign currency translation adjustments	'	'	'	'	-41,000
Balance, ending	1,655,000	'	1,655,000	'	1,642,000
Less: accumulated amortization [Abstract]	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-477,000	-613,000	-613,000
Amortization expense	'	'	-102,000	'	-140,000
Write Off Of In Process Research And Development Amortization	'	'	'	'	238,000
Foreign currency translation adjustments	-13,000	'	-13,000	'	38,000
Accumulated amortization, ending balance	-592,000	'	-592,000	'	-477,000
Net balance	1,063,000	'	1,063,000	'	1,165,000
Weighted average life (in years)	'	'	'11 years	'	'9 years
Minimum [Member]	'	'	'	'	'
Intangible Assets [Line Items]	'	'	'	'	'
Research and Development Expense, Estimated	'	'	4,000,000	'	'
Maximum [Member]	'	'	'	'	'
Intangible Assets [Line Items]	'	'	'	'	'
Research and Development Expense, Estimated	'	'	7,000,000	'	'
Goodwill [Member]	'	'	'	'	'
Intangible Assets [Line Items]	'	'	'	'	'
Asset Impairment Charges	($1,159,000)	'	'	'	$0

OTHER_COMPREHENSIVE_LOSS_INCOM2

OTHER COMPREHENSIVE (LOSS) INCOME (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2013	'	'	$419	'
Other comprehensive loss before reclassifications	'	'	-821	'
Amounts reclassified from accumulated other comprehensive (loss) income	'	'	-7	'
Net current-period other comprehensive loss	-425	107	-828	-516
Ending balance, September 30, 2014	-409	'	-409	'
Available-for-sale Securities [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2013	'	'	0	'
Other comprehensive loss before reclassifications	'	'	-7	'
Amounts reclassified from accumulated other comprehensive (loss) income	'	'	-7	'
Net current-period other comprehensive loss	'	'	-14	'
Ending balance, September 30, 2014	-14	'	-14	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2013	'	'	419	'
Other comprehensive loss before reclassifications	'	'	-814	'
Amounts reclassified from accumulated other comprehensive (loss) income	'	'	0	'
Net current-period other comprehensive loss	'	'	-814	'
Ending balance, September 30, 2014	($395)	'	($395)	'

OTHER_COMPREHENSIVE_LOSS_INCOM3

OTHER COMPREHENSIVE (LOSS) INCOME (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Foreign currency translation adjustments, before tax	($410)	'	($814)	'
Foreign currency translation adjustments, tax benefit	0	'	0	'
Foreign currency translation adjustments, net of tax	-410	'	-814	'
Unrealized gains on available-for-sale investments, before tax	-24	'	-23	'
Unrealized gains on available-for-sale investments, tax benefit	9	'	9	'
Unrealized gains on available-for-sale investments, net of tax	-15	'	-14	'
Other comprehensive (loss) income, before tax	-434	'	-837	'
Other comprehensive (loss) income, tax benefit	9	'	9	'
Other comprehensive (loss) income, net of tax	($425)	$107	($828)	($516)

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net income	$5,550	$796	$16,241	$1,980
Denominator:	'	'	'	'
Denominator for basic net income per share - weighted average common stock outstanding	41,714,000	40,752,000	41,496,000	40,712,000
Effect of dilutive securities: stock options and awards	667,000	1,167,000	631,000	1,059,000
Denominator for diluted net income per share - weighted average shares outstanding - diluted	42,381,000	41,919,000	42,127,000	41,771,000
Basic net income per share	$0.13	$0.02	$0.39	$0.05
Diluted net income per share	$0.13	$0.02	$0.39	$0.05
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive restricted stock awards, stock options	167,929	189,445	167,929	189,445

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 30, 2014
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$1
Unrecognized compensation costs, weighted average period of recognition (in years)	'1 year 1 month 21 days
Stock Options [Member]	'
Stock options, outstanding [Roll Forward]	'
Options outstanding, beginning balance (in shares)	967
Granted (in shares)	0
Exercised (in shares)	-311
Cancelled or expired (in shares)	-25
Options outstanding, ending balance (in shares)	631
Stock options, additional Disclosures [Abstract]	'
Weighted-average price, beginning of period (in dollars per share)	$15.35
Weighted-average price, granted (in dollars per share)	$0
Weighted average price, exercised (in dollars per share)	$9.73
Weighted-average price, cancelled or expired (in dollars per share)	$19.85
Weighted-average price, end of period (in dollars per share)	$17.94
Restricted Stock [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	18.5
Unrecognized compensation costs, weighted average period of recognition (in years)	'2 years 11 months 27 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	826
Granted (in shares)	535
Vested (in shares)	-285
Cancelled or expired (in shares)	-59
Non-vested, ending balance (in shares)	1,017
Equity instruments other than options, additional Disclosures [Abstract]	'
Non-vested, beginning balance (in dollars per share)	$18.62
Granted (in dollars per share)	$20.04
Vested (in dollars per share)	$18.08
Cancelled or expired (in dollars per share)	$19.23
Non-vested, ending balance (in dollars per share)	$19.48
Restricted Stock Units (RSUs) [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$4.30
Unrecognized compensation costs, weighted average period of recognition (in years)	'2 years 7 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	833
Granted (in shares)	139
Vested (in shares)	-59
Cancelled or expired (in shares)	-168
Non-vested, ending balance (in shares)	745

STOCKBASED_COMPENSATION_Detail1

STOCK-BASED COMPENSATION (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cost of revenue	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	$233	$233	$743	$635
Research and development	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	726	675	1,862	1,892
Selling, general and administrative	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	1,663	981	4,447	4,206
Selling, general and administrative	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	$2,622	$1,889	$7,052	$6,733

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Segment Reporting [Abstract]	'	'	'	'	'
Number of segments for financial reporting purposes (in number of segments)	2	'	2	'	'
Intersegment sales	$3,600,000	$2,200,000	$9,000,000	$7,900,000	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	56,684,000	50,780,000	168,877,000	158,267,000	'
Depreciation and amortization	3,400,000	3,994,000	10,935,000	11,747,000	'
Operating profit (loss)	4,996,000	-4,194,000	17,952,000	-705,000	'
Assets	330,512,000	293,896,000	330,512,000	293,896,000	306,046,000
Technology and Strategic Partnerships [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	32,645,000	33,335,000	98,094,000	96,352,000	'
Depreciation and amortization	1,655,000	2,087,000	5,373,000	5,826,000	'
Operating profit (loss)	8,792,000	9,293,000	27,348,000	23,368,000	'
Assets	174,548,000	187,422,000	174,548,000	187,422,000	'
Assays and Related Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	24,039,000	17,445,000	70,783,000	61,915,000	'
Depreciation and amortization	1,745,000	1,907,000	5,562,000	5,921,000	'
Operating profit (loss)	-3,796,000	-13,487,000	-9,396,000	-24,073,000	'
Assets	$155,964,000	$106,474,000	$155,964,000	$106,474,000	'

ACCRUED_WARRANTY_COSTS_Details

ACCRUED WARRANTY COSTS (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Accrued warranty costs [Roll Forward]	'
Accrued warranty costs at December 31, 2013	$721
Warranty expenses incurred	728
Accrual for warranty costs	-773
Accrued warranty costs at September 30, 2014	$676

INCOME_TAXES_Details

INCOME TAXES (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]	'	'
Effective tax rate, including amounts recorded for discrete events (in hundredths)	9.30%	20.00%
Statutory rate (in hundredths)	35.00%	'
Maximum rate for cash taxes expected to be paid (in hundredths)	50.00%	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Distribution Agreement Settlement Expense	$7